Pending mechanistic insight into the role of metabolism, inhibition of MCL-1 and BCL-XL, either directly or by targeting upstream regulators, might be most achievable in order to overcome venetoclax resistance in MCL. The gene discussed is BCL2L1; the disease is mantle cell lymphoma.